Aptevo Therapeutics (APVO) Accumulated Depreciation & Amortization (2016 - 2024)
Aptevo Therapeutics' Accumulated Depreciation & Amortization history spans 10 years, with the latest figure at $13.9 million for Q4 2024.
- For Q4 2024, Accumulated Depreciation & Amortization rose 2.59% year-over-year to $13.9 million; the TTM value through Dec 2024 reached $13.9 million, up 2.59%, while the annual FY2024 figure was $13.9 million, 2.59% up from the prior year.
- Accumulated Depreciation & Amortization for Q4 2024 was $13.9 million at Aptevo Therapeutics, up from $13.6 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $13.9 million in Q4 2024 and bottomed at $11.1 million in Q4 2020.
- The 5-year median for Accumulated Depreciation & Amortization is $13.0 million (2022), against an average of $12.8 million.
- The largest annual shift saw Accumulated Depreciation & Amortization increased 12.28% in 2020 before it increased 2.59% in 2024.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $11.1 million in 2020, then rose by 10.19% to $12.3 million in 2021, then grew by 6.08% to $13.0 million in 2022, then rose by 4.35% to $13.6 million in 2023, then increased by 2.59% to $13.9 million in 2024.
- Per Business Quant, the three most recent readings for APVO's Accumulated Depreciation & Amortization are $13.9 million (Q4 2024), $13.6 million (Q4 2023), and $13.0 million (Q4 2022).